Adverse effects associated with allopurinol
Patient 1 | Patient 2 | Patient 3 | Patient 4 | Patient 5 | |
Group | A | A | A | B | B |
Age (years) | 56 | 66 | 36 | 56 | 60 |
Duration of the disease (years) | 12 | 23 | 16 | 29 | 3.3 |
Previous duration of treatment (months) | 5 | 32 | 0.5 | 6 | 18 |
Allopurinol maintenance doses (mg/day) | 300 | 300 | 300 | 300 | 300 |
CrC (ml/min) | 115.8 | 92 | 108 | 80 | 61.2 |
Adverse event | Rash | Rash | AHS | FPE | Leucocytoclastic vasculitis |
Subsequent ULD | Allopurinol reinitiated | Allopurinol reinitiated | Allopurinol reinitiated2-150 | Allopurinol reinitiated | Allopurinol reinitiated |
CrC = creatinine clearance; AHS = allopurinol hypersensitivity syndrome; FPE = fixed pigmented drug eruption; ULD = urate lowering drug.
↵2-150 Allopurinol was reinitiated after the patient received benzobromarone for 6 years without adequate response and after desensitisation, as described in Results section.17